Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population

World Journal of Gastroenterology

Volumn 20, Issue 38, 2014, Pages 14010-14017

  Li, Min Rui ^a   Zhang, Sheng Hong ^a   Chao, Kang ^a   Liao, Xian Hua ^a   Yao, Jia Yan ^a   Chen, Min Hu ^a   Zhong, Bi Hui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apolipoprotein C3; Insulin resistance; Metabolic disorder; Nonalcoholic fatty liver disease; Polymorphism

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN C3;

ADULT; AGE; APOLIPOPROTEIN C3 GENE; ARTICLE; BODY MASS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; UNIVERSITY HOSPITAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHI SQUARE DISTRIBUTION; CHINA; COMORBIDITY; EPIDEMIOLOGY; ETHNOLOGY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PHENOTYPE; RISK; RISK FACTOR; STATISTICAL MODEL;

ADULT; APOLIPOPROTEIN C-III; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; COMORBIDITY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS, UNIVERSITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84910001923     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i38.14010     Document Type: Article

References (42)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
2. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210 [PMID: 19014878 DOI: 10.1016/j.jhep.2008.10]
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193]
4. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]
5. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]
6. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992; 33: 995-1003 [PMID: 1431591]
7. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249: 790-793 [PMID: 2167514]
8. Lee HY, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, Popov V, Frederick DW, Zhang D, Guigni B, Bharadwaj KG, Choi CS, Goldberg IJ, Park JH, Petersen KF, Samuel VT, Shulman GI. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011; 54: 1650-1660 [PMID: 21793029]
9. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-1089 [PMID: 20335584 DOI: 10.1056/NEJMoa0907295]
10. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53: 467-474 [PMID: 21274868 DOI: 10.1002/Hep.24072]
11. Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, Coccia F, Cossu E, Leonetti F, Baroni MG. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis 2011; 10: 93 [PMID: 21663607 DOI: 10.1186/1476-511X-10-93]
12. Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O, Orho-Melander M, Yki-Järvinen H. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2012; 27: 951-956 [PMID: 22141340 DOI: 10.1111/j.1440-1746.2011.07045.x]
13. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). J Dig Dis 2011; 12: 38-44 [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010]
14. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63 [PMID: 10857969]
15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480 [PMID: 16681555 DOI: 10.1111/j.1464-5491]
16. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431-1446 [PMID: 23024028 DOI: 10.1002/acr.21772]
17. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56: e50-103 [PMID: 21144964 DOI: 10.1016/j.jacc.2010]
18. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis 2000; 150: 149-157 [PMID: 10781646]
19. Li Y, Xing C, Cohen JC, Hobbs HH. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 2012; 55: 327-328 [PMID: 21898508 DOI: 10.1002/hep.24659]
20. Niu TH, Jiang M, Xin YN, Jiang XJ, Lin ZH, Xuan SY. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. World J Gastroenterol 2014; 20: 3655-3662 [PMID: 24707151 DOI: 10.3748/wjg.v20.i13.3655]
21. Ding Y, Zhu MA, Wang ZX, Zhu J, Feng JB, Li DS. Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol 2012; 2012: 509420 [PMID: 22675253 DOI: 10.1155/2012/509420]
22. Yu J, Huang J, Liang Y, Qin B, He S, Xiao J, Wang H, Zhong R. Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China. Lipids Health Dis 2011; 10: 200 [PMID: 22054125 DOI: 10.1186/1476-511X-10-200]
23. Lallukka S, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013; 56: 886-892 [PMID: 23334462]
24. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350 [PMID: 12021250 DOI: 10.1172/JCI15001]
25. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028 [PMID: 12107194 DOI: 10.1210/jcem.87.7.8638]
26. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-608 [PMID: 15734833]
27. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353 [PMID: 15166226 DOI: 10.1074/jbc.M313478200]
28. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007; 117: 739-745 [PMID: 17318260 DOI: 10.1172/JCI30400]
29. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 2005; 54: 664-671 [PMID: 15734841]
30. Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab 2013; 39: 16-26 [PMID: 23266468 DOI: 10.1016/j.diabet.2012.11.002]
31. Pollex RL, Ban MR, Young TK, Bjerregaard P, Anand SS, Yusuf S, Zinman B, Harris SB, Hanley AJ, Connelly PW, Huff MW, Hegele RA. Association between the -455T& gt; C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. BMC Med Genet 2007; 8: 80 [PMID: 18096054 DOI: 10.1186/1471-2350-8-80]
32. Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, Dwivedi M, Misra A. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007; 38: 444-451 [PMID: 17416293 DOI: 10.1016/j.arcmed.2006.10.013]
33. Guettier JM, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, Deepa R, Gross M, Rao G, Mohan V. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. J Clin Endocrinol Metab 2005; 90: 1705-1711 [PMID: 15598690 DOI: 10.1210/jc.2004-1338]
34. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Srisopha S, Nitiyanontakij R, Tengtrakulcharoen P, Tarkowski M, Riva A, Nakayama EE, Shioda T. Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. AIDS Res Hum Retroviruses 2013; 29: 142-150 [PMID: 22775001 DOI: 10.1089/AID.2012.0114]
35. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322: 1702-1705 [PMID: 19074352 DOI: 10.1126/science.1161524]
36. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90: 4562-4566 [PMID: 8099442]
37. Waterworth DM, Talmud PJ, Humphries SE, Wicks PD, Sagnella GA, Strazzullo P, Alberti KG, Cook DG, Cappuccio FP. Variable effects of the APOC3-482C > T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. Diabetologia 2001; 44: 245-248 [PMID: 11270684 DOI: 10.1007/s001250051607]
38. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96: 2601-2605 [PMID: 8675624 DOI: 10.1172/JCI118324]
39. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 472-484 [PMID: 10073946]
40. Cooper AD. Role of the liver in the degradation of lipoproteins. Gastroenterology 1985; 88: 192-205 [PMID: 2981081]
41. Windler EE, Greeve J, Daerr WH, Greten H. Binding of rat chylomicrons and their remnants to the hepatic low-density-lipoprotein receptor and its role in remnant removal. Biochem J 1988; 252: 553-561 [PMID: 3415673]
42. Sherrill BC, Dietschy JM. Characterization of the sinusoidal transport process responsible for uptake of chylomicrons by the liver. J Biol Chem 1978; 253: 1859-1867 [PMID: 632244]